Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042764 | 0.82 | CES2 (0.36) | ACHECES2CES1TAAR1ALDH1A1 | |
| SCHEMBL8035545 | 0.71 | CES2 (0.32) | CES2CES1ALDH1A1ERN1 | |
| SCHEMBL1039758 | 0.71 | CES2 (0.36) | ACHECES2CES1BCHENFE2L2 | |
| SCHEMBL19968584 | 0.71 | CES2 (0.36) | ACHECES2CES1ALDH1A1BCHE | |
| SCHEMBL30426297 | 0.69 | ACHE (0.38) | ACHECES2CES1TAAR1ALDH1A1 | |
| SCHEMBL2154282 | 0.69 | ACHE (0.38) | ACHECES2CES1TAAR1ALDH1A1 | |
| SCHEMBL1041826 | 0.68 | MAPT (0.39) | ALDH1A1GAA | |
| SCHEMBL1040594 | 0.68 | CYP2A6 (0.45) | ALDH1A1 | |
| SCHEMBL1041734 | 0.68 | CA2 (0.40) | ALDH1A1 | |
| SCHEMBL1041027 | 0.67 | ACHE (0.48) | ACHECES2CES1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896607-B | Olefin oligomerization process using a catalyst comprising a chromium complex having a phosphacycle-containing ligand | 陶氏环球技术有限责任公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20220176363-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-06-09 | — | — | US | disclosed |
| CN-107548385-B | Olefin oligomerization process using catalyst comprising chromium complex with phosphacycle-containing ligand | 陶氏环球技术有限责任公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113896607-A | Olefin oligomerization process using catalyst comprising chromium complex with phosphacycle-containing ligand | 陶氏环球技术有限责任公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-107592863-B | Chromium complexes with ligands containing phosphacycles and olefin oligomerization catalysts therefrom | 陶氏环球技术有限责任公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-107567355-B | Phosphacycle-containing ligands for chromium complexes and olefin oligomerization catalysts therefrom | 陶氏环球技术有限责任公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210129125-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-05-06 | — | — | US | disclosed |
| US-10981156-B2 | Chromium complex and catalyst therefrom | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10919031-B2 | Process for oligomerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200338542-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10702861-B2 | Process for oligomerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200030783-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-10376869-B2 | Process for oligomerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-10357764-B2 | Phosphacycle compound and process for production thereof | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190210013-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-10207262-B2 | Chromium complex and catalyst therefrom | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180154344-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180071725-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-03-15 | — | — | US | disclosed |
| US-6084133-A | REACTING A PHOSPHINE HALIDE WITH A METAL, THEN PROTONATION RESULTING DIORGANO-SUBSTITUTED METAL PHOSPHIDE; SIMPLIFICATION, NONTOXIC, EFFICIENCY | KANKYO KAGAKU CENTER CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210129125-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | ACHE 307/4885CES2 1949/4885CES1 1272/4885 |
| US-20200338542-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | ACHE 307/4885CES2 1949/4885CES1 1272/4885 |
| US-20180071725-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | OXER1, LIG1, PICALM | ACHE 110/4885CES2 994/4885CES1 745/4885 |
| US-10919031-B2 | Process for oligomerization | OXER1, NOD1, LIG1 | ACHE 307/4885CES2 1949/4885CES1 1272/4885 |
| US-10376869-B2 | Process for oligomerization | OXER1, NOD1, LIG1 | ACHE 307/4885CES2 1949/4885CES1 1272/4885 |
| US-10981156-B2 | Chromium complex and catalyst therefrom | OXER1, LIG1, PICALM | ACHE 110/4885CES2 994/4885CES1 745/4885 |
| US-10357764-B2 | Phosphacycle compound and process for production thereof | OXER1, PPIP5K2, IP6K1 | ACHE 182/4885CES2 1582/4885CES1 709/4885 |
| US-10207262-B2 | Chromium complex and catalyst therefrom | OXER1, LIG1, PICALM | ACHE 110/4885CES2 994/4885CES1 745/4885 |
| US-20200030783-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | ACHE 307/4885CES2 1949/4885CES1 1272/4885 |
| US-20180154344-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | ACHE 307/4885CES2 1949/4885CES1 1272/4885 |
| US-20220176363-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | ACHE 307/4885CES2 1949/4885CES1 1272/4885 |
| US-20190210013-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | OXER1, LIG1, PICALM | ACHE 110/4885CES2 994/4885CES1 745/4885 |
| US-10702861-B2 | Process for oligomerization | OXER1, NOD1, LIG1 | ACHE 307/4885CES2 1949/4885CES1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.